SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
The following is the text of an advertisement prepared by ICN
Pharmaceuticals, Inc. and appearing in the Wall Street Journal on May 7, 2002:
ICN LEADERSHIP
CLEAR STRATEGY
INDEPENDENT BOARD OF DIRECTORS
|o| Developed world's second largest biotechnology drug franchise
|o| Restructuring plan with tangible results
|o| Successful Ribapharm IPO raised $299 million
|o| Record operating results full year 2001 and first quarter 2002
versus
THE DISSIDENTS
NO LONG TERM PLAN
NO DISCLOSED STRATEGY
|x| Recent shareholders
|x| Since January 2001: total of at least 195 trades in ICN,
including 62 sales
|x| No disclosed long term objectives
|x| No experience managing a global pharmaceutical company
Vote for Proven Performance. [ICN LOGO] Vote ICN Nominees.
VOTE THE GOLD PROXY CARD
----
If you have any questions or need assistance
voting your shares, please call:
MORROW & CO., INC.
Call 1-800-607-0088